MALAT1 overexpression was shown to be related with markers of poor prognosis in prostate cancer, which includes a high Gleason result, advanced stage of tumor node metastasis, and serum PSA levels that were greater than 20 ng/mL. Here, MALAT1 is linked to prostate carcinoma.